PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAzathioprine
Imuran, Jayempi(azathioprine)
Azasan, Azathioprine, Imuran, Jayempi (azathioprine) is a small molecule pharmaceutical. Azathioprine was first approved as Imuran on 1982-01-01. It is used to treat crohn disease, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and thrombocytopenic purpura idiopathic amongst others in the USA. It has been approved in Europe to treat graft rejection.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
digestive system diseasesD004066
nervous system diseasesD009422
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
immune system phenomenaD055633
Trade Name
FDA
EMA
Azasan, Azathioprine, Imuran (discontinued: Imuran)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Azathioprine
Tradename
Company
Number
Date
Products
IMURANSebela PharmaceuticalsN-016324 RX1982-01-01
1 products, RLD, RS
Show 1 discontinued
Azathioprine sodium
Tradename
Company
Number
Date
Products
IMURANCasper PharmaN-017391 DISCN1982-01-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
azasanANDA2024-10-17
azathioprineANDA2025-02-05
azathioprine sodiumANDA2025-01-23
imuranNew Drug Application2024-07-20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AX: Other immunosuppressants in atc
L04AX01: Azathioprine
HCPCS
Code
Description
J7500
Azathioprine, oral, 50 mg
J7501
Azathioprine, parenteral, 100 mg
Clinical
Clinical Trials
297 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Crohn diseaseD003424EFO_0000384K50314132252
Ulcerative colitisD003093EFO_0000729K512371325
Inflammatory bowel diseasesD015212EFO_00037671141824
NephritisD009393N051692421
Lupus nephritisD008181EFO_00057611682420
VasculitisD014657EFO_0006803M316103220
ColitisD003092EFO_0003872K52.9237820
Systemic lupus erythematosusD008180EFO_0002690M324761319
Intestinal diseasesD007410K63.9131115
UlcerD014456MPATH_579234615
Show 55 more
Indications Phases 2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DermatitisD003872L30.9156
Therapeutic equivalencyD01381011
Cutaneous lupus erythematosusD008178EFO_0003834L93.111
Photosensitivity disordersD010787L57.111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L2044
Autoimmune diseasesD001327EFO_0000540M30-M3633
Multiple sclerosisD009103EFO_0003885G3522
Choroidal neovascularizationD02025611
Pathologic neovascularizationD00938911
Squamous intraepithelial lesionsD00008148311
Retinal diseasesD012164H35.911
ScleritisD015423H15.011
LipidosesD008064E75.611
Herpes zosterD006562EFO_0006510B0211
Show 21 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAzathioprine
INNazathioprine
Description
Azathioprine is a thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS. It has a role as an antineoplastic agent, an antimetabolite, an immunosuppressive agent, a prodrug, a carcinogenic agent, a DNA synthesis inhibitor and a hepatotoxic agent. It is a thiopurine, a C-nitro compound, a member of imidazoles and an aryl sulfide.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2[nH]cnc12
Identifiers
PDB
CAS-ID446-86-6
RxCUI
ChEMBL IDCHEMBL1542
ChEBI ID2948
PubChem CID2265
DrugBankDB00993
UNII IDMRK240IY2L (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Azathioprine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 55,860 documents
View more details
Safety
Black-box Warning
Black-box warning for: Azasan, Azathioprine, Imuran
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
38,530 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use